Symbol lookup for: "SGN"
8 Results
Symbol | Company Name | Type | Stock Price | Market Cap |
---|---|---|---|---|
SGN | Signing Day Sports, Inc. | Stock | 1.00 | 3.62M |
WSE:SGN | Sygnity S.A. | Stock | 100.00 | 2.25B |
HOSE:SGN | Saigon Ground Services JSC | Stock | 63,900.00 | 2,162.92B |
TSXV:SGN | Scorpio Gold Corporation | Stock | 0.20 | 44.27M |
BOM:531812 | SGN Telecoms Limited | Stock | 0.70 | 67.88M |
TSX:SGNL | Signal Gold Inc. | Stock | 0.09 | 21.68M |
SGNLF | Signal Gold Inc. | Stock | 0.06 | 15.23M |
SGNFX | Sparrow Growth Fund No-Load Class | Mutual Fund | 48.71 | 23.55M |
News search for "SGN"
SIGNING DAY SPORTS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Signing Day Sports, Inc. - SGN
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger o...
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease
The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023 Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tech...